Literature DB >> 9088024

Allelic loss on chromosomes 3p, 5q and 17p in renal cell carcinomas.

J Sugimura1, G Tamura, Y Suzuki, T Fujioka.   

Abstract

Loss-of-heterozygosity (LOH) has been studied on 3p (von Hippel-Lindau gene locus), 5q and 17p (p53 gene locus) by a polymerase chain reaction (PCR)-based strategy in 42 sporadic renal cell carcinomas (RCC). LOH at seven microsatellite loci on 5q was investigated because a tumor suppressor gene on 5q involved in the development and/or progression of RCC has not yet been identified. LOH was found in seven (17%) RCC at single or multiple loci on 5q, 38% (11/29 informative cases) on 3p, and 6% (2/35 informative cases) on 17p. Replication error (RER) was present in 10% (4/42) RCC at single or multiple loci. The minimum region of deletion on 5q to account for LOH was mapped to 5q31.1 (interferon regulatory factor-1; IRF-1 locus), where LOH was detected in 23% (6/26 informative cases). LOH on 3p and 5q occurred in both stage 2 and more advanced (stage 3 and 4) tumors at similar incidences (41 and 33% on 3p; and 24 and 22% on 5q, respectively), suggesting that LOH on these chromosomes is an early genetic event. All RCC exhibiting LOH on 3p or 5q (IRF-1 locus) were the clear cell or the mixed clear and granular cell types. These findings suggest that LOH on 3p and 5q plays an important role in the genesis of clear cell RCC. In addition, only one tumor exhibited LOH on both 3p and 5q, which suggests that LOH occurs not sequentially but independently.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088024     DOI: 10.1111/j.1440-1827.1997.tb03724.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

Review 1.  Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines.

Authors:  Wen-Chi L Chang; Terry V Zenser; Harry S Cooper; Margie L Clapper
Journal:  Cancer Lett       Date:  2013-02-13       Impact factor: 8.679

2.  IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation.

Authors:  Feifei Chen; Jian Song; Jiehui Di; Qing Zhang; Hui Tian; Junnian Zheng
Journal:  Tumour Biol       Date:  2012-08-14

3.  Establishment and characterization of a highly immunogenic human renal carcinoma cell line.

Authors:  Clelia Prattichizzo; Margherita Gigante; Paola Pontrelli; Alessandro Stella; Maria Teresa Rocchetti; Maddalena Gigante; Eugenio Maiorano; Wolfgang Herr; Michele Battaglia; Loreto Gesualdo; Elena Ranieri
Journal:  Int J Oncol       Date:  2016-05-27       Impact factor: 5.650

4.  Novel IRF-1 Mutations in a Small Cohort of Leukaemia Patients From Saudi Arabia

Authors:  Khaldoon Alsamman; Xiuli Zhang; Chittibabu Vatte; Mohammad Al Hamad; Omar S El-Masry; Amani Y Owaidah; Faisal Alzahrani; Yao Lin
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26

Review 5.  Interferon regulatory factor 1 inactivation in human cancer.

Authors:  Khaldoon Alsamman; Omar S El-Masry
Journal:  Biosci Rep       Date:  2018-05-08       Impact factor: 3.840

6.  IRF-1 Inhibits Angiogenic Activity of HPV16 E6 Oncoprotein in Cervical Cancer.

Authors:  Seung Bae Rho; Seung-Hoon Lee; Hyun-Jung Byun; Boh-Ram Kim; Chang Hoon Lee
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

7.  Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma.

Authors:  Till Eichenauer; Navid Shadanpour; Martina Kluth; Cosima Göbel; Sören Weidemann; Christoph Fraune; Franziska Büscheck; Claudia Hube-Magg; Christina Möller-Koop; Roland Dahlem; Margit Fisch; Michael Rink; Silke Riechardt; Eike Burandt; Christian Bernreuther; Sarah Minner; Ronald Simon; Guido Sauter; Waldemar Wilczak; Till Clauditz
Journal:  World J Surg Oncol       Date:  2020-06-13       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.